Identification of Aldo-Keto reductase AKR1B10 as a selective target for modification and inhibition by prostaglandin A1: Implications for antitumoral activity

Cancer Research

Volumn 71, Issue 12, 2011, Pages 4161-4171

  Díez Dacal, Beatriz ^a   Gayarre, Javier ^a   Gharbi, Severine ^c   Timms, John F ^c   Coderch, Claire ^b   Gago, Federico ^b   Pérez Sala, Dolores ^a  

^a CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

^b UNIVERSITY OF ALCALÁ   (Spain)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIHYDRO 2,8 DIISOPROPYL 3 THIOXO 2H 1,4 BENZOXAZINE 4 ACETIC ACID; ALDEHYDE REDUCTASE; ALDEHYDE REDUCTASE RELAPTED PROTEIN 2; ALDOSE REDUCTASE INHIBITOR; CYCLOPENTENONE; CYSTEINE; DAUNORUBICIN; DOXORUBICIN; FENOFIBRATE; GLUTATHIONE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HISTIDINE; PROSTAGLANDIN A1; PROTEIN AKR1B10; PROTEIN S 100; TYROSINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CARCINOGENICITY; CELL CYCLE ARREST; CELL FRACTIONATION; CELL SURVIVAL; CONTROLLED STUDY; COVALENT BOND; DOSE RESPONSE; EMBRYO; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MODIFICATION; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LIQUID CHROMATOGRAPHY; LUNG ADENOCARCINOMA; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOLECULAR MODEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN MODIFICATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; WESTERN BLOTTING;

ALDEHYDE REDUCTASE; AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; CERCOPITHECUS AETHIOPS; COS CELLS; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; HUMANS; MICE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NIH 3T3 CELLS; PROSTAGLANDINS A;

EID: 79958856252     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-3816     Document Type: Article

References (48)

1. 2 inhibition of NF-κB DNA binding through covalent modification of the p50 subunit. J Biol Chem 2001;276:35530-6.
2. Levonen AL, Dickinson DA, Moellering DR, Mulcahy RT, Forman HJ, Darley-Usmar VM. Biphasic effects of 15-deoxy-delta(12,14)-prostaglandin J(2) on glutathione induction and apoptosis in human endothelial cells. Arterioscler Thromb Vasc Biol 2001;21:1846-51.
3. Díez-Dacal B, Pérez-Sala D. Anti-inflammatory prostanoids: focus on the interactions between electrophile signalling and resolution of inflammation. Scientific World Journal 2010;10:655-75.
4. 2 addition in mesangial cells: role in the inhibition of pro-inflammatory genes. Mol Pharmacol 2004;66:1349-58.
5. Shiraki T, Kamiya N, Shiki S, Kodama TS, Kakizuka A, Jingami H. α,β-unsaturated ketone is a core moiety of natural ligands for covalent binding to peroxisome proliferator-activated receptor. J Biol Chem 2005;280:14145-53. (Pubitemid 40517317)
6. 12,14-prostaglandin J2. J Biol Chem 2003;278:51251-60.
7. Rossi A, Kapahi P, Natoli G, Takahashi T, Chen Y, Karin M, et al. Antiinflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase. Nature 2000;403:103-8. (Pubitemid 30038530)
8. Straus DS, Pascual G, Li M, Welch JS, Ricote M, Hsiang CH, et al. 15-deoxy-delta(12,14)-prostaglandin J2 inhibits multiple steps in the NF-kappaB signaling pathway. Proc Natl Acad Sci U S A 2000;97:4844-9.
9. Renedo M, Gayarre J, García-Domínguez CA, Pérez-Rodríguez A, Prieto A, Cañada FJ, et al. Modification and activation of Ras proteins by electrophilic prostanoids with different structure are site-selective. Biochemistry 2007;46:6607-16. (Pubitemid 46870126)
10. 2: role of glutathione. FEBS Lett 2005;579:5803-8.
11. Doyle K, Fitzpatrick FA. Redox signaling, alkylation (carbonylation) of conserved cysteines inactivates class I histone deacetylases 1, 2, and 3 and antagonizes their transcriptional repressor function. J Biol Chem 2010;285:17417-24.
12. Petrash JM. All in the family: aldose reductase and closely related aldo-keto reductases. Cell Mol Life Sci 2004;61:737-49. (Pubitemid 38659658)
13. Cao D, Fan ST, Chung SS. Identification and characterization of a novel human aldose reductase-like gene. J Biol Chem 1998;273:11429-35. (Pubitemid 28272034)
14. Fukumoto S, Yamauchi N, Moriguchi H, Hippo Y, Watanabe A, Shibahara J, et al. Overexpression of the aldo-keto reductase family protein AKR1B10 is highly correlated with smokers' non-small cell lung carcinomas. Clin Cancer Res 2005;11:1776-85. (Pubitemid 40471839)
15. Kim B, Lee HJ, Choi HY, Shin Y, Nam S, Seo G, et al. Clinical validity of the lung cancer biomarkers identified by bioinformatics analysis of public expression data. Cancer Res 2007;67:7431-8. (Pubitemid 47206573)
16. Satow R, Shitashige M, Kanai Y, Takeshita F, Ojima H, Jigami T, et al. Combined functional genome survey of therapeutic targets for hepatocellular carcinoma. Clin Cancer Res 2010;16:2518-28.
17. Li CP, Goto A, Watanabe A, Murata K, Ota S, Niki T, et al. AKR1B10 in usual interstitial pneumonia: expression in squamous metaplasia in association with smoking and lung cancer. Pathol Res Pract 2008; 204:295-304.
18. Gallego O, Ruiz FX, Ardevol A, Dominguez M, Alvarez R, de Lera AR, et al. Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10. Proc Natl Acad Sci U S A 2007;104:20764-9.
19. Ruiz FX, Gallego O, Ardevol A, Moro A, Dominguez M, Alvarez S, et al. Aldo-keto reductases from the AKR1B subfamily: retinoid specificity and control of cellular retinoic acid levels. Chem Biol Interact 2009;178:171-7.
20. Martin HJ, Breyer-Pfaff U, Wsol V, Venz S, Block S, Maser E. Purification and characterization of AKR1B10 from human liver: role in carbonyl reduction of xenobiotics. Drug Metab Dispos 2006; 34:464-70. (Pubitemid 43290905)
21. Hausding M, Witteck A, Rodríguez-Pascual F, von Eichel-Streiber C, Fostermann U, Kleinert H. Inhibition of small G proteins of the Rhofamily by statins or clostridium difficile toxin B enhances cytokine-mediated induction of NO synthase II. Br J Pharmacol 2000;131:553-61.
22. Edgell CJ, McDonald CC, Graham JB. Permanent cell line expressing human factor VIII-related antigen established by hybridization. Proc Natl Acad Sci USA 1983;80:3734-7. (Pubitemid 13063134)
23. 1 allows assessment of PPAR-independent effects and identification of novel cellular targets for covalent modification. Chem Biol Interact 2010;183:212-21.
24. George R, Chan HL, Ahmed Z, Suen KM, Stevens CN, Levitt JA, et al. A complex of Shc and Ran-GTPase localises to the cell nucleus. Cell Mol Life Sci 2009;66:711-20.
25. Gharbi S, Gaffney P, Yang A, Zvelebil MJ, Cramer R, Waterfield MD, et al. Evaluation of two-dimensional differential gel electrophoresis for proteomic expression analysis of a model breast cancer cell system. Mol Cell Proteomics 2002;1:91-8.
26. Gordon JC, Myers JB, Folta T, Shoja V, Heath LS, Onufriev A. H++: a server for estimating pKas and adding missing hydrogens to macromolecules. Nucleic Acids Res 2005;33:W368-71.
27. Cornell W, Cieplak P, Bayly C, Gould I, Merz K, Ferguson D, et al. A second generation force field for the simulation of proteins, nucleic acids and organic molecules. J Am Chem Soc 1995;117:5179-97.
28. Morris G, Goodsell D, Halliday R, Huey R, Hart W, Belew R, et al. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 1998;19: 1639-62. (Pubitemid 128590223)
29. Aroui S, Brahim S, Waard MD, Kenani A. Cytotoxicity, intracellular distribution and uptake of doxorubicin and doxorubicin coupled to cell-penetrating peptides in different cell lines: a comparative study. Biochem Biophys Res Commun 2010;391:419-25.
30. Ogretmen B, Schady D, Usta J, Wood R, Kraveka JM, Luberto C, et al. Role of ceramide in mediating the inhibition of telomerase activity in A549 human lung adenocarcinoma cells. J Biol Chem 2001; 276:24901-10.
31. Sánchez-Gómez FJ, Díez-Dacal B, Pajares MA, Llorca O, Pérez-Sala D. Cyclopentenone prostaglandins with dienone structure promote cross-linking of the chemoresistance-inducing enzyme glutathione transferase P1-1. Mol Pharmacol 2010;78:723-33.
32. Balendiran GK, Martin HJ, El-Hawari Y, Maser E. Cancer biomarker AKR1B10 and carbonyl metabolism. Chem Biol Interact 2009;178: 134-7.
33. Bohren KM, Grimshaw CE, Lai CJ, Harrison DH, Ringe D, Petsko GA, et al. Tyrosine-48 is the proton donor and histidine-110 directs substrate stereochemical selectivity in the reduction reaction of human aldose reductase: enzyme kinetics and crystal structure of the Y48H mutant enzyme. Biochemistry 1994;33:2021-32. (Pubitemid 24099596)
34. Verma M, Martin HJ, Haq W, O'Connor TR, Maser E, Balendiran GK. Inhibiting wild-type and C299S mutant AKR1B10; a homologue of aldose reductase upregulated in cancers. Eur J Pharmacol 2008;584:213-21.
35. Ohtori A, Yamamoto Y, Tojo KJ. Penetration and binding of aldosereductase inhibitors in the lens. Invest Ophthalmol Vis Sci 1991; 32:189-93.
36. 1 methyl esters with thiols. J Am Chem Soc 1997;119:2376-85.
37. Veitch ZW, Guo B, Hembruff SL, Bewick AJ, Heibein AD, Eng J, et al. Induction of 1C aldoketoreductases and other drug dose-dependent genes upon acquisition of anthracycline resistance. Pharmacogenet Genomics 2009;19:477-88.
38. Stravopodis DJ, Karkoulis PK, Konstantakou EG, Melachroinou S, Lampidonis AD, Anastasiou D, et al. Grade-dependent effects on cell cycle progression and apoptosis in response to doxorubicin in human bladder cancer cell lines. Int J Oncol 2009;34:137-60.
39. Dan S, Yamori T. Repression of cyclin B1 expression after treatment with adriamycin, but not cisplatin in human lung cancer A549 cells. Biochem Biophys Res Commun 2001;280:861-7. (Pubitemid 32924511)
40. Goto S, Ihara Y, Urata Y, Izumi S, Abe K, Koji T, et al. Doxorubicin-induced DNA intercalation and scavenging by nuclear glutathione Stransferase pi. FASEB J 2001;15:2702-14. (Pubitemid 33131096)
41. Endo S, Matsunaga T, Soda M, Tajima K, Zhao HT, El-Kabbani O, et al. Selective inhibition of the tumor marker AKR1B10 by antiinflammatory n-phenylanthranilic acids and glycyrrhetic acid. Biol Pharm Bull 2010;33:886-90.
42. Song DG, Lee JY, Lee EH, Jung SH, Nho CW, Cha KH, et al. Inhibitory effects of polyphenols isolated from Rhus verniciflua on aldo-keto reductase family 1 B10. BMB Rep 2010;43:268-72.
43. Matsunaga T, Endo S, Soda M, Zhao HT, El-Kabbani O, Tajima K, et al. Potent and selective inhibition of the tumor marker AKR1B10 by bisdemethoxycurcumin: probing the active site of the enzyme with molecular modeling and site-directed mutagenesis. Biochem Biophys Res Commun 2009;389:128-32.
44. Garzón B, Oeste CL, Díez-Dacal B, Pérez-Sala D. Proteomic studies on protein modification by cyclopentenone prostaglandins: expanding our view on electrophile actions. J Proteomics 2011. [Epub ahead of print].
45. Quinn AM, Harvey RG, Penning TM. Oxidation of PAH trans-dihydrodiols by human aldo-keto reductase AKR1B10. Chem Res Toxicol 2008;21:2207-15.
46. Oze I, Hotta K, Kiura K, Ochi N, Takigawa N, Fujiwara Y, et al. Twenty-seven years of phase III trials for patients with extensive disease small-cell lung cancer: disappointing results. PLoS One 2009;4:e7835.
47. Hurley LH. DNA and its associated processes as targets for cancer therapy. Nat Rev Cancer 2002;2:188-200. (Pubitemid 37328788)
48. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004;56:185-229. (Pubitemid 38720829)